Table 3.
Clinicopathological characteristics of breast cancer patients and controls of testing and validation cohorts: cohort #2 and cohort #3.
| Plasma Samples | ||||
|---|---|---|---|---|
| Cohort #2 | Cohort #3 | |||
| Breast Cancer Patients | Controls | Breast Cancer Patients | Controls | |
| Number | 105 | 98 | 89 | 85 |
| Median age, years (range) | 52 (29–82) | 50 (40–64) | 54.1(32–92) | 55 (32–90) |
| Histological subtype, n (%) | ||||
| Luminal | 92 (87.6%) | n.a. | 54 (60.7%) | n.a. |
| TNBC | 7 (6.7%) | 15 (16.9%) | ||
| Her 2-enriched | 5 (4.8%) | 18 (20.2%) | ||
| Unknown | 1 (1%) | 2 (2.2%) | ||
| Grade group, n (%) | ||||
| 1 | 8 (7.6%) | n.a. | 19 (21.3%) | n.a. |
| 2 | 54 (51.4%) | 44 (49.4%) | ||
| 3 | 39 (37.1%) | 25 (28.1%) | ||
| Unknown | 4 (3.8%) | 1 (1.1%) | ||
| Stage, n (%) | ||||
| I | 42 (40%) | n.a. | 24 (27.0%) | n.a. |
| II | 18 (17.1%) | 41 (46.1%) | ||
| III | 32 (30.5%) | 15 (16.3%) | ||
| IV | 13 (12.4%) | 5 (5.4%) | ||
| Unknown | 4 (4.3%) | |||
| Pathological T stage, n (%) | ||||
| pT1 | 46 (43.8%) | n.a. | 36 (40.4%) | n.a. |
| pT2 | 29 (27.6%) | 37 (41.6%) | ||
| pT3 | 18 (17.1%) | 9 (10.1%) | ||
| pT4 | 10 (9.5%) | 1 (1.1%) | ||
| Unknown | 2 (1.9%) | 6 (6.7%) | ||
| Regional lymph node metastasis, n (%) | ||||
| No | 53 (50.5%) | n.a. | 47 (52.8%) | n.a. |
| Yes | 50 (47.6%) | 36 (40.4%) | ||
| Unknown | 2 (1.9%) | 6 (6.7%) | ||
| Distant metastasis, n (%) | ||||
| No | 92 (87.6%) | n.a. | 80 (89.9%) | n.a. |
| Yes | 13 (12.4%) | 7 (7.9%) | ||
| Unknown | 2 (2.2%) | |||
| TNBC, triple-negative breast cancer; n.a., not applicable | ||||